New PET scan aims to spot hidden cancer spread

NCT ID NCT05394259

Recruiting now Diagnosis Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study is testing whether a special PET scan using a drug called PYLARIFY can better detect cancer that has spread in people with pancreatic cancer, liver cancer, or breast cancer. About 36 adults will receive the scan, and doctors will compare the results to standard methods to see how accurate it is. The goal is to improve how doctors find metastases, which could guide treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Piflufolastat F18 (PYLARIFY)
What this could lead to: If successful, this imaging agent could help doctors more accurately detect where cancer has spread in patients with pancreatic, liver, or breast cancer.
What could go wrong: This is a very early pilot study with only 36 participants. The imaging agent may not prove accurate enough to replace current methods, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hepatocellular carcinoma invasive lobular breast carcinoma malignant pancreatic neoplasm pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER HEPATOCELLULAR CARCINOMA PANCREATIC CANCER

Contacts and locations

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.